Virtual Global Expert Program: Patrice Milos
Innovative Technologies Enabling Drug Development
Dr Patrice Milos has been a visionary leader in the field of precision health for more than 30 years. Dr Milos currently serves as an Advisor to the Rhode Island Life Science Hub, serves on the RI Bio Board and ProThera Biologics Board and is a member of the RI Hub Venture Mentoring Services.
A serial entrepreneur, Dr Milos served as the Vice President of Scientific Operations at Proof Diagnostics, Inc. (sold to Ginkgo Bioworks, Inc.) where she brought her passion of enabling individuals to make informed health decisions using science and novel technology.
Patrice also co-founded Medley Genomics, a RI startup emerging from Brown University, to deliver novel data analytics for understanding the heterogeneity of complex diseases with a focus in oncology.
Prior to Medley, she was CEO of Claritas Genomics, a pediatric molecular diagnostic company spun-out of Boston Children’s Hospital. As Boston Site Head for Pfizer’s Centers of Therapeutic Innovation, Patrice was instrumental in advancing novel therapeutic programs to treat human disease. She was also SVP/CSO for Helicos BioSciences in Cambridge, Mass., and Executive Director for Pfizer Inc., responsible for leading a broad platform of genomics supporting precision medicine across the company.
Patrice was recently a member of the Brown University Biomedical Innovations to Impact Fund and Slater Technology Fund Board. She’s also senior advisor to several biotech companies including Ribbon Biolabs and has been an active NIH grant reviewer. Patrice also served on the RI Economic Development Planning Council. She earned her M.S./Ph.D. at Rensselaer Polytechnic Institute with postdoctoral fellowships at Brown and Harvard.
What we'll cover:
Sharing real-world experience in supporting pharma/biotech innovators, we will explore:
An overview of pharmaceutical drug development timelines.
The dramatic inflection of novel sequencing technologies, their development and application to rare disease gene identification.
The role of molecular diagnostics, including point-of-care, in identifying causative gene mutations.
The emergence of gene therapy and other novel modalities to treat rare diseases.
About the Virtual Global Expert Program
Getting time with the right expert at the right moment can change the trajectory of a company. We're making that easier to access across WA.
This program connects WA innovators directly with international experts — people who have built companies, raised capital, navigated regulatory pathways, and opened international markets in the sectors you're working in.
Five themed virtual sessions with leading global practitioners, plus limited 1:1 office hours available to deep dive further.
Presented by the WA Life Sciences Innovation Hub, with the support of the Government of Western Australia Department of Energy and Economic Diversification.